Activating transcription factor 3 and cancer progression

Project: Research

Status	Finished
Effective start/end date	1/01/14 → 31/12/17

ATF3 repression of BCL-X_L determines apoptotic sensitivity to HDAC inhibitors across tumor types
Chüeh, A. C., Tse, J. W. T., Dickinson, M., Ioannidis, P., Jenkins, L., Togel, L., Tan, B. S., Luk, I., Davalos-Salas, M., Nightingale, R., Thompson, M. R., Williams, B. R. G., Lessene, G., Lee, E. F., Fairlie, W. D., Dhillon, A. S. & Mariadason, J. M., 15 Sep 2017, In: Clinical Cancer Research. 23, 18, p. 5573-5584 12 p.
Research output: Contribution to journal › Article › Research › peer-review

30 Citations (Scopus)
Overexpression of the transcription factor ATF3 with a regulatory molecular signature associates with the pathogenic development of colorectal cancer
Yan, F., Ying, L., Li, X., Qiao, B., Meng, Q., Yu, L., Yuan, X., Ren, S. T., Chan, D. W., Shi, L., Ni, P., Wang, X., Xu, D. & Hu, Y., 2017, In: Oncotarget. 8, 29, p. 47020-47036 17 p.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

18 Citations (Scopus)
Activating transcription factor 3 expression as a marker of response to the histone deacetylase inhibitor pracinostat
Sooraj, D., Xu, D., Cain, J. E., Gold, D. P. & Williams, B. R. G., 1 Jul 2016, In: Molecular Cancer Therapeutics. 15, 7, p. 1726-1739 14 p.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

7 Citations (Scopus)

Project Details